Lenvatinib (new indication: advanced renal cell carcinoma, 1st line, in combination with pembrolizumab)


  • Active Substance: Lenvatinib
  • Name: Kisplyx®
  • Therapeutic area: Renal cell carcinoma
  • Pharmaceutical company: Eisai GmbH

Time table:

  • Start: 15.01.2022
  • Final decision by G-BA: 07.07.2022

Final decision:

  • Patients with a favorable risk profile (IMDC Score 0):
    • No additional benefit proved
  • Patients with an intermediary (IMDC Risk Score 1-2) favorable risk profile (IMDC Score ≥ 3):
    • No additional benefit proved